IBI 322
Alternative Names: Anti-CD47/PD-L1 bispecific antibody; IBI-322; Recombinant anti-human CD47/PD-L1 bispecific antibody - Innovent BiologicsLatest Information Update: 17 Oct 2023
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD4-positive T-lymphocyte stimulants; CD47 antigen inhibitors; Phagocyte stimulants; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Haematological malignancies; Solid tumours
Most Recent Events
- 17 Oct 2023 IBI 322 is still in phase I trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT04328831)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral, Injection)
- 28 Aug 2023 Innovent Biologics completes a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT04328831)